Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

CRSP CRISPR Therapeutics AG
$56.27 5.16% +2.79
Notify me if price changes either direction
Interactive Brokers Logotype

Buy CRSP stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 5.2B
Enterprise value 3.4B
Trailing PE -8.7727975270479
Forward PE -12.853063
PEG Ratio -12.853063
Enterprise to EBITDA -6.126
Enterprise to revenue 957.918
Price to book MRQ 2.6675315
Price to sales TTM 1461.93

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2025-12-31
Revenue (TTM) 3.5M
EBITDA -548838976
Diluted EPS TTM -6.47
Total Cash (MRQ) 2.0B
Current ratio (MRQ) 13.316
Operating Cash Flow (TTM) -345014016

CRSP trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent CRSP News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.